NanoViricides, Inc. (NYSE American: NNVC) has drawn attention to its broad-spectrum antiviral candidate NV-387 in light of the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could provide a differentiated approach if proven effective against the virus strain. NV-387’s proposed mechanism targets viral cell attachment pathways that are common across filoviruses, positioning it as a potential tool for pandemic preparedness against Ebola and related viral threats.
According to the press release, the company emphasized that NV-387’s mechanism of action could be advantageous for combating filoviruses, including the Bundibugyo strain currently circulating. The oral formulation of NV-387 is highlighted as a key differentiator, potentially enabling easier administration in outbreak settings compared to injectable treatments. The full press release can be accessed at https://ibn.fm/mm3Z5.
NanoViricides is a clinical-stage company focused on developing special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as mpox/smallpox and measles. The company’s technology is based on the TheraCour nanomedicine platform, which it licenses from TheraCour Pharma, Inc.
The company also noted that it holds exclusive licenses for developing drugs against a range of viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes simplex, influenza, dengue, Japanese encephalitis, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses. NanoViricides is currently advancing NV-387 toward Phase II human clinical trials.
As with all drug development, the company cautioned that there can be no assurance that NV-387 or any of its candidates will demonstrate sufficient safety and efficacy for regulatory approval. The path to market is lengthy and requires substantial capital. Investors can find the latest news and updates about NNVC at https://ibn.fm/NNVC.
The announcement comes as health authorities respond to the Bundibugyo Ebola outbreak, underscoring the need for effective treatments against emerging viral threats. While NV-387 has not yet been tested against this specific strain, its broad-spectrum design offers a theoretical advantage. The company’s focus on oral administration could also address logistical challenges in resource-limited settings. However, clinical validation remains a critical next step.
